Listen on the go
CORRECT!
Next question
touchENDOCRINOLOGY touchENDOCRINOLOGY

Trending Activities
Endocrine Oncology
CE/CME ACCREDITED
touchEXPERT OPINIONS
Advancing the management of adult solid tumours in 2023, and beyond: Unlocking the potential of radiopharmaceuticals
Dr Ana Kiess, Dr Stephen Graves, Dr Jason Starr, Prof. Jorge Garcia, Dr Erik Mittra
Watch Time: 53 mins

Following a scientific primer, the role of radiopharmaceuticals in the management of neuroendocrine tumours and prostate cancer, alongside approaches to support clinical implementation, are explored by leading experts.

Learning objectives
Learning Objectives
  • Describe the underlying rationale and mechanism of action for radiopharmaceuticals in adult oncology
  • Recall the different types of radiopharmaceuticals (approved and in clinical development), and their specific properties
  • Summarize the latest efficacy and safety data available for radiopharmaceuticals in the management of adult solid tumours, including potential implications for current and future clinical practice
  • Propose strategies to support integration of radiopharmaceuticals into adult oncology pathways to individualize clinical management, and ultimately, optimize patient outcomes
Diabetes, Cardiovascular Risk, Obesity
CE/CME ACCREDITED
touchMDT
The future for glycemic control and weight loss in T2D and obesity: Incretin-based dual agonists and optimizing patient education
Prof. Carol Wysham, Dr Ken Fujioka, Ms Jennifer Okemah, Patient: Ms. Brittany Jones
Watch Time: 37 mins

Watch specialists within an MDT plus a patient discuss incretin-based dual agonists and educational strategies for patients with T2D and obesity

Learning objectives
Learning Objectives
  • Recognize the effect of incretin hormones and glucagon on metabolism in wellness and in T2D
  • Evaluate the rationale and latest evidence for incretin-based dual-agonist therapies in patients with T2D and obesity
  • Apply early treatment intensification, weight loss and patient education strategies in patients with T2D and obesity

All Activities

View all IME activities

Endocrine Oncology
Watch Time: 53 mins
touchEXPERT OPINIONS
Advancing the management of adult solid tumours in 2023, and beyond: Unlocking the potential of radiopharmaceuticals
CE/CME ACCREDITED Dr Ana Kiess, Dr Stephen Graves, Dr Jason Starr, Prof. Jorge Garcia, Dr Erik Mittra

Following a scientific primer, the role of radiopharmaceuticals in the management of neuroendocrine tumours and prostate cancer, alongside approaches to support clinical implementation, are explored by leading experts.

Learning objectives
Learning Objectives
  • Describe the underlying rationale and mechanism of action for radiopharmaceuticals in adult oncology
  • Recall the different types of radiopharmaceuticals (approved and in clinical development), and their specific properties
  • Summarize the latest efficacy and safety data available for radiopharmaceuticals in the management of adult solid tumours, including potential implications for current and future clinical practice
  • Propose strategies to support integration of radiopharmaceuticals into adult oncology pathways to individualize clinical management, and ultimately, optimize patient outcomes
Pituitary Disorders
Watch Time: 34 mins
touchMDT
Multidisciplinary insights for Cushing’s disease: Individualized medical management of patients for whom surgery is not an option or not curative
CE/CME ACCREDITED Dr Laurence Katznelson, Dr Timothy Smith, Mrs Sandra Ramsburg, Ms Sharmyn McGraw

Hear multidisciplinary team and patient insights on the medical management of Cushing’s disease.

Chronic Kidney Disease
Watch Time: 34 mins
touchPANEL DISCUSSION
Key considerations for the clinical management of rapidly progressing ADPKD
CE/CME ACCREDITED Prof. Bradley Erickson, Prof. Neera Dahl, Prof. Charles Vega

Watch three experts discuss the clinical management of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD).

Learning objectives
Learning Objectives
  • Recognize how to predict progression in patients with ADPKD
  • Discuss the efficacy data for the currently available and emerging pharmacological treatment options for rapidly progressing ADPKD
  • Discuss how to manage key side effects when using vasopressin V2 receptor antagonists in ADPKD
Paediatric Endocrinology
Watch Time: 34 mins
touchEXPERT OPINIONS
Improving the alpha-mannosidosis patient journey
CE/CME ACCREDITED Professor Barbara K Burton

An expert gives her perspectives on the history and prevalence of alpha-mannosidosis, its diagnosis and treatment options

Learning objectives
Learning Objectives
  • Describe the prevalence and natural history of the rare lysosomal storage disorder alpha-mannosidosis (AM)
  • Explain how diagnosis of AM may be approached, and describe the methods of disease identification
  • Outline current and emerging management and treatment options for patients with AM
Liver Disorders
Watch Time: 38 mins
touchIN CONVERSATION
Achieving best practice management of primary biliary cholangitis, now and in the future
CE/CME ACCREDITED Dr Palak Trivedi, Prof. Gideon Hirschfield Translations available:

Watch two specialists in autoimmune liver disease discuss best practice in the management of primary biliary cholangitis, including assessing emerging therapies and personalization of care.

Learning objectives
Learning Objectives
  • Describe the recommendations for diagnosis and management of patients with primary biliary cholangitis
  • Evaluate emerging treatment options for patients with primary biliary cholangitis
  • Review and implement individualized management for patients with primary biliary cholangitis
Reproductive Endocrinology
Watch Time: 51 mins
touchCONGRESS
Scanning the horizon of pharmacological treatments for women experiencing vasomotor symptoms during menopause: What’s new in 2022?
CE/CME ACCREDITED Prof. Steven Goldstein, Dr Samuel Lederman, Prof. JoAnn Pinkerton

Watch this two-part activity exploring the latest data on pharmacological treatments for vasomotor symptoms (VMS) associated with menopause. Filmed following the 2022 North American Menopause Society (NAMS) Annual Meeting and the International Menopause Society (IMS) 18th World Congress on Menopause. Part 1: Watch menopause expert Prof. Steven Goldstein review key data from the 2022 NAMS Annual Meeting and the IMS 18th World Congress on Menopause Watch Now Part 2: Choose from leading menopause experts who discuss what these data may mean for clinical practice in the USA Select An Interview

Learning objectives
Learning Objectives
  • Describe the benefits and risks of hormone therapy for vasomotor symptoms associated with menopause
  • Outline the rationale for non-hormonal therapy and mechanisms of action of emerging options for the treatment of vasomotor symptoms associated with menopause
  • Recall the latest data for emerging non-hormonal therapies for the treatment of vasomotor symptoms associated with menopause
Diabetes, Cardiovascular Risk
Watch Time: 48 mins
touchMDT
Multidisciplinary insights on the role of GLP-1 RAs in the modern management of stroke in patients with T2D
CE/CME ACCREDITED Dr Yassir Javaid, Prof. Georgios Tsivgoulis, Prof. Tina Vilsbøll, Ms Hyvelle Ferguson-Davis Translations available:

A multidisciplinary team and a patient discuss GLP-1 RAs and their role in stroke prevention in patients with T2D.

Learning objectives
Learning Objectives
  • Describe the burden of stroke and risk factors for stroke in patients with T2D
  • Evaluate the latest data for GLP-1 RAs in the context of stroke management and prevention
  • Interpret current treatment guidelines for T2D in the context of stroke management and prevention and apply it to clinical practice
Chronic Kidney Disease, Cardiovascular Risk, Diabetes
Watch Time: 38 mins
touchIN CONVERSATION
Addressing cardiorenal outcomes in CKD and T2D: What are the key considerations for daily practice?
CE/CME ACCREDITED Prof. Peter Rossing, Dr Eden Miller Translations available:

Watch experts in endocrinology and in primary care discuss key considerations for addressing cardiorenal outcomes in patients with CKD/T2D

Learning objectives
Learning Objectives
  • Identify the epidemiological and pathophysiological drivers behind the progression of CKD
  • Recognize the specific renal and cardiovascular risks associated with CKD and T2D and the therapies available to address them
  • Apply the latest clinical guidelines to treating patients with CKD and T2D in daily practice
Endocrine Oncology
Watch Time: 45 mins
touchMDT
Advancing the multidisciplinary management of rare and unusual NETs: Integrating new approaches to treatment and care
CE/CME ACCREDITED Dr Diane Reidy-Lagunes, Prof. Dr med. Marianne Pavel, Dr Thomas Hope, Catherine Bouvier Ellis

Watch leading specialists involved in the multidisciplinary care of patients with rare and unusual neuroendocrine tumours discuss new and emerging approaches for diagnosis and treatment.

Learning objectives
Learning Objectives
  • Recognize the role of the MDT in addressing diagnostic and treatment challenges associated with rare and unusual neuroendocrine tumours (NETs)
  • Evaluate the factors guiding treatment selection and clinical management decisions in rare and unusual NETs
  • Appraise the efficacy and safety of new and emerging treatment options for rare and unusual NETs
Bone Disorders, Paediatric Endocrinology
Watch Time: 35 mins
touchIN CONVERSATION
Paediatric growth patterns and their impact on health: Achondroplasia in focus
CE/CME ACCREDITED Dr Nadia Merchant, Dr Andrew Dauber Translations available:

Watch experts in paediatric endocrinology discuss the physiology of normal and abnormal bone growth, and the assessment and treatment of achondroplasia.

Learning objectives
Learning Objectives
  • Explain how the mechanisms behind various bone growth control systems contribute to bone health and bone abnormalities
  • Use appropriate growth charts to detect abnormal growth patterns in children
  • Summarize the linear growth patterns, and physical and radiographic findings indicative of achondroplasia, and the impact of emerging treatments
Diabetes, Cardiovascular Risk, Obesity
Watch Time: 39 mins
touchMDT
Integrating GLP-1 RAs into T2D management: A unified approach, from PCP to patient
CE/CME ACCREDITED Dr Kevin Fernando, Prof. Dr med. Michael Nauck, Prof. Dr Şeyda Özcan, Ms Kelly Ann Hardy

Watch specialists within an MDT, plus a patient, discuss the role of GLP-1 RAs in the management of T2D.

Learning objectives
Learning Objectives
  • Evaluate the data supporting the use of GLP-1 RAs for treatment of T2D and apply them to practical considerations associated with GLP-1 RA use
  • Manage potential side effects of GLP-1 RAs, including GI symptoms, and discuss self-management with patients
  • Recognize the role of GLP-1 RAs in the T2D management pathway and apply this knowledge to clinical practice
Diabetes, Cardiovascular Risk, Obesity
Watch Time: 37 mins
touchMDT
The future for glycemic control and weight loss in T2D and obesity: Incretin-based dual agonists and optimizing patient education
CE/CME ACCREDITED Prof. Carol Wysham, Dr Ken Fujioka, Ms Jennifer Okemah, Patient: Ms. Brittany Jones

Watch specialists within an MDT plus a patient discuss incretin-based dual agonists and educational strategies for patients with T2D and obesity

Learning objectives
Learning Objectives
  • Recognize the effect of incretin hormones and glucagon on metabolism in wellness and in T2D
  • Evaluate the rationale and latest evidence for incretin-based dual-agonist therapies in patients with T2D and obesity
  • Apply early treatment intensification, weight loss and patient education strategies in patients with T2D and obesity
Endocrine Oncology, Thyroid Disorders
Watch Time: 41 mins
touchEXPERT OPINIONS
Personalized treatment of RET-altered thyroid cancers: What is the value of biomarker testing and targeted therapies?
CE/CME ACCREDITED Prof. Maria Cabanillas, Dr Vivek Subbiah, Dr Lori Wirth

Leading experts explain the value of biomarker testing and targeted therapies for the personalized treatment of RET-altered thyroid cancers

Learning objectives
Learning Objectives
  • Distinguish between different types of thyroid cancers and describe therapies that are appropriate for their management
  • Plan a personalized approach to treatment of RET-altered thyroid cancers, including use of biomarker testing and novel targeted therapies
  • Evaluate the clinical trial data for novel targeted therapies for RET-altered thyroid cancers and apply it to clinical practice
Cardiovascular Risk, Diabetes, Chronic Kidney Disease
Watch Time: 38 mins
touchPANEL DISCUSSION
Progress in the management of CKD in patients with type 2 diabetes: How might non-steroidal MRAs change the treatment paradigm?
CE/CME ACCREDITED Prof. Christoph Wanner, Prof. Javed Butler, Prof. Janet McGill Translations available:

Experts discuss the evidence for non-steroidal mineralocorticoid receptor antagonists (MRAs) as an additional treatment option for patients with type 2 diabetes (T2D) and chronic kidney disease (CKD).

Learning objectives
Learning Objectives
  • Evaluate the need for new treatment options for patients with T2D and CKD
  • Justify the use of MRAs in patients with T2D and CKD and describe the cardiorenal efficacy and safety of new and emerging nonsteroidal MRAs
  • Appraise how nonsteroidal MRAs can address unmet needs in patients with T2D and CKD and fit into the current treatment paradigm
Endocrine Oncology
Watch Time: 36 mins
touchPANEL DISCUSSION
Perspectives on the current status and recent advances in GEP-NETs
CE/CME ACCREDITED Prof. Jonathan R Strosberg, Dr Jennifer Chan, Prof. Dr. med. Marianne Pavel

Explore current perspectives on the management of GEP-NETs through this panel discussion, highlighting emerging data presented at the ESMO Congress 2021.

Diabetes, Cardiovascular Risk, Obesity
Watch Time: 44 mins
touchMDT
Antihyperglycemic therapy in the patient with T2D and obesity: A multidisciplinary outlook
CE/CME ACCREDITED Prof. Dr. med Michael Nauck, Prof. Stewart Harris, Dr Shannon Idzik, Ms Tammie Snowden Translations available:

Watch leading specialists within an MDT plus a patient with T2D discuss the use of antihyperglycemic therapies to control both T2D and obesity

Learning objectives
Learning Objectives
  • Describe the relationship between T2D and obesity
  • Predict the beneficial effects of weight loss with a GLP-1 RA based therapy or SGLT2i on outcomes in patients with T2D and obesity
  • Perform appropriate selection of antihyperglycemic therapy with weight-loss benefits for patients with T2D and obesity
Diabetes
Watch Time: 41 mins
touchIN CONVERSATION
Achieving individualized glycemic targets in patients with type 2 diabetes: What are the key considerations?
CE/CME ACCREDITED Dr Joanna Van, Dr Vincent Woo Translations available:

Watch experts in diabetes management discuss the key considerations when applying and achieving individualized glycemic targets in patients with type 2 diabetes.

Learning objectives
Learning Objectives
  • Evaluate the unmet need regarding achieving glycemic control in patients with type 2 diabetes and the associated reasons
  • Decide how to apply individualized glycemic targets according to patient characteristics
  • Choose appropriate treatments with properties relevant to the individual patient to help achieve glycemic control
Cardiovascular Risk
Watch Time: 43 Mins
touchMDT
What promise do novel lipoprotein-lowering therapies hold for effectively reducing ASCVD risk? Perspectives from a multidisciplinary team
CE/CME ACCREDITED Prof. Lawrence Leiter, Dr Constantine Kosmas, Dr Yassir Javaid

Select a discussion in the hub to watch our multidisciplinary faculty share their insights on how novel lipoprotein-lowering therapies can help to reduce ASCVD risk and what this may mean for patient care in the future.

Endocrine Oncology
Watch Time: 35 mins
touchEXPERT OPINIONS
Optimizing the management of gastroenteropancreatic neuroendocrine tumours
CE/CME ACCREDITED Prof. Jonathan R Strosberg, Dr Diane Reidy-Lagunes, Prof. Thorvardur R Halfdanarson

Watch leading experts explore how recent scientific and clinical advances may optimize the medical management of gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in 2021, and beyond.

IME
CME activities are developed by touchIME for touchENDOCRINOLOGY.

Our education resources are developed in collaboration with our well established peer-reviewed medical journals, our Editorial Board members and partnerships with major medical societies, with a clear commitment to high-quality independent education.

Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72